GSK in partnership with Department of Health and Human Services
The Biomedical Advanced Research and Development Authority (BARDA) is part of the U.S. Department of Health and Human Services (HHS). This agreement with GSK is a first of its kind collaboration.
This public-private agreement marks the first time that HHS has taken a "portfolio approach" to funding drug development with a private sector company. This unique collaboration provides flexibility to move funding around GSK's antibacterial portfolio, rather than focusing on just one drug candidate and allow medicines to be studied for the potential treatment of both conventional and biothreat pathogens.
Under the terms of the agreement, HHS will provide $40 million for the initial 18-month agreement and up to a total of $200 million if the agreement is renewed over five years. The treatment of drug resistant bacterial infections is predicted to become a global crisis due to the scarcity of new antibiotics in the pharmaceutical industry's pipeline and a decrease in investment in research and development.
"There is an urgent need to address antibiotic resistance and new models are needed to deal with this challenging area of drug development," said David Payne, head of GSK's Antibacterial Discovery Performance Unit.
The work under this agreement will be governed by a BARDA-GSK joint oversight committee that will monitor progress, make decisions on the allocation of funds and decide on the addition or removal of drug candidates from the portfolio. In March, GSK and the Texas A&M System and GlaxoSmithKline received U.S. government approval to establish an influenza vaccine facility in Texas. GSK is one of the few large pharmaceutical companies still pursuing antibacterial research. ■